Advertisement

Prodrugs pp 1195-1205 | Cite as

Case Study: Cefuroxime Axetil: An Oral Prodrug of Cefuroxime

  • Tarra Fuchs
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Cefuroxime axetil (Ceftin®, Zinnat®) was designed to be an oral form of cefuroxime (Zinacef®), a second-generation cephalosporin antibiotic available by IV and IM injection (O’Callaghan et al., 1976; Brogden et al., 1979; Emmerson, 1988). Cefuroxime is a useful antibiotic because it is a broad-spectrum antibiotic, effective against bacterial strains with β-lactamase activity (Dürckheimer et al., 1985; Kees and Grobecker, 1995). The parenteral cefuroxime, like other cephalosporins, is not orally absorbed because it contains a highly polar carboxyl group that is ionized at intestinal pH, making transport across intestinal mucosa unlikely (Foord, 1976; Tsuji et al., 1986). An attempt to deliver the free acid orally led to only 1% of the drug recovered in the urine (Foord, 1976).

Keywords

Antimicrob Agent Cefuroxime Axetil Lactam Antibiotic Film Coated Tablet Ethyl Bromide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anon. Ceftin® [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline. 2003aGoogle Scholar
  2. Anon. Zinacef® [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline. 2003bGoogle Scholar
  3. Brogden RN, Heel RC, Speight TM, and Avery GS. Cefuroxime: A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use. Drugs 1979; 17:233–266PubMedCrossRefGoogle Scholar
  4. Bundgaard H. Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities. In: Bundgaard, H. Design of Prodrugs. New York, NY Elsevier Science Publishing Co. 1985:1–92Google Scholar
  5. Carson JWK, Watters K, Taylor MRH, and Keane CT. Clinical Trials of Cefuroxime Axetil in Children. J Antimicrob Chemother 1987; 19:109–112PubMedCrossRefGoogle Scholar
  6. Dantzig AH, Duckworth DC, and Tabas LB. Transport Mechanisms Responsible of the Absorption of Loracarbef, Cefixime and Cefuroxime Axetil into Human Intestinal Caco-2 Cells. Biochim Biophys Acta 1994, 1191:7–13CrossRefGoogle Scholar
  7. Dürckheimer W, Blumbach J, Lattrell R, and Scheunemann KH. New Developments in β-Lactam Antibiotics. Angew Chemie 1985; 97:183–205CrossRefGoogle Scholar
  8. Emmerson AE. Cefuroxime Axetil. J Antimicrob Chemother 1988; 22:101–104PubMedCrossRefGoogle Scholar
  9. Felisi C, Longoni D, Alpegiani M, and Cabri W. A Process for the Preparation of Highly Pure Cefuroxime Axetil. PCT Int Appl WO 2003014126 (February 20) 2003Google Scholar
  10. Ferres H. Pro-Drugs of β-Lactam Antibiotics. Drugs Today 1983; 19:499–538Google Scholar
  11. Finn A, Straughn A, Meyer M, and Chubb J. Effect of Dose and Food on the Bioavailability of Cefuroxime Axetil. Biopharm Drug Dispos 1987; 8:519–526PubMedCrossRefGoogle Scholar
  12. Foord RD. Cefuroxime: Human Pharmacokinetics. Antimicrob Agents Chemother 1976; 9:741–747PubMedGoogle Scholar
  13. Harding SM, Williams PEO and Ayrtron J. Pharmacology of Cefuroxime and the Acetoxylethyl Ester in Volunteers. Antimicrob Agents Chemother 1984; 25:78–82PubMedGoogle Scholar
  14. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, and Collins JJ. Clinical Comparison of Cefuroxime Axetil and Amoxicillin/Clavulanate in the Treatment of Patients with Secondary Bacterial Infections of Acute Bronchitis. Clin Ther 1995;17:861–874PubMedCrossRefGoogle Scholar
  15. Huber FM, Chauvette RR, and Jackson BG. Preparative Methods for 7-Aminocephalosporanic Acid and 6-Aminopenicillanic acid. In: Flynn, EH. Cephalosporins and Penicillins: Chemistry and Biology New York, NY: Academic Press; 1972:27–73Google Scholar
  16. Hwang T-S and Ahn C-Y. New Method for Preparation of Amorphous Cefuroxime Axetil. PCT Int Appl WO 2002016372 (February 28) 2002Google Scholar
  17. Kansal VK, Bhat SG, Marutikumar TV, and Chavan YA. An Improved Method for Preparation of Cefuroxime Axetil. PCT Int Appl WO 2003010170 (February 6) 2003Google Scholar
  18. Kees F and Grobecker, H. Systematics of Beta-Lactams: Chemical Properties and Structure Activity Relationship of Oral Cephalosporins. Antibiot Chemother (Basel) 1995; 47(Oral Cephalosporins):1–7PubMedGoogle Scholar
  19. Kees F, Lukassek U, Naber KG, and Grobecker H. Comparative Investigation of the Bioavailability of Cefuroxime Axetil. Arzneim-Forsch/Drug Res 1991; 41(II):843–846Google Scholar
  20. Lang CC, Moreland TA, and Davey PG. Bioavailability of Cefuroxime Axetil: Comparison of Standard and Abbreviated Methods. J Antimicrob Chemother 1990; 25:645–650PubMedCrossRefGoogle Scholar
  21. Langan C, Clecner B, Cazzola CM, Brambilla C, Holmes CY, and Staley H. Shortcourse cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Prac 1998; 52:289–297Google Scholar
  22. Longoni D, Alpegiani M, Cabri W, and Felisi C. Industrial-Scale Process for the Preparation of Crystalline Cefuroxime Axetil from Cefuroxime Sodium and 1-(Acetoxy)ethyl Bromide. PCT Int Appl WO 2003024977 (March 27) 2003Google Scholar
  23. Moellering RC and Swartz MN. The Newer Cephalosporins. New Engl J Med 1976; 294:24–28PubMedGoogle Scholar
  24. Mosher-Gerald L, McBee J, and Shaw DB. Esterase Activity Toward the Diastereomers of Cefuroxime Axetil in Rat and Dog. Pharm Res 1992; 9:687–689CrossRefGoogle Scholar
  25. Nomura H, Fugono T, Hitaka T, Minami I, Azuma T, Morimoto S, and Masuda T. Semisynthetic β-lactam Antibiotics. 6. Sulfocephalosporins and Their Antipseudomonal Activities. J Med Chem 1974; 17:1312–1315PubMedCrossRefGoogle Scholar
  26. Novelli A, Mazzei T, Fallani S, Dei R, Cassetta MI, and Conti S. Betalactam Therapy and Intestinal Flora. J Chemotherapy (Florence) 1995; 7(Suppl. 1):25–32Google Scholar
  27. O’Callaghan CH, Skyes RB, Griffiths A, and Thornton JE. Cefuroxime, a New Cephalosporin Antibiotic: Activity In Vitro Antimicrob Agents Chemother 1976; 9:511–519Google Scholar
  28. Perry CM and Brodgen RN. Cefuroxime Axetil: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy Drugs 1996; 53:125–158CrossRefGoogle Scholar
  29. Sasinowska-Motyl M, Wisniewska I, Gumulka W. Oszczapowicz I. Szelachowska M, and Interewicz B. Esters of cephalosporins. I. Permeability of cefuroxime liberated from its 1-acetoxyethyl ester through biological membranes; influence of the form and size of the ester particles. Acta Pol Pharm 1995; 52; 391–395PubMedGoogle Scholar
  30. Scott LJ, Ormrod D and Goa KL. Cefuroxime Axetil: An Updated Review of its Uses in the Management of Bacterial Infections Drugs 2001; 61:1454–1500CrossRefGoogle Scholar
  31. Silverman RB. The Organic Chemistry of Drug Design and Drug Action. Burlington,MA: Elsevier Academic Press; 2004. 617pGoogle Scholar
  32. Singh SK, Tiwari RP, and Jain P. A Novel and Efficient Synthesis of (6R,7R)-7-Amino-3-hydroxymethyl Cephalosporanic Acid: A Versatile Precursor of Cefuroxime Acid. Synthetic Commun 2003; 33:2475–2482.CrossRefGoogle Scholar
  33. Sommers DK, van Wyk M, Williams PEO, and Harding SM. Pharmacokinetics and Tolerance of Cefuroxime Axetil in Volunteers During Repeated Dosing. Antimicrob Agents Chemother 1984; 25:344–347PubMedGoogle Scholar
  34. Ruiz-Balaguer N, Nacher A, and Casabo VG. Nonlinear Intestinal Absorption Kinetics of Cefuroxime Axetil in Rats. Antimicrob Agents Chemother 1997; 41:445–448PubMedGoogle Scholar
  35. Ruiz-Balaguer N, Nacher A, Casabo VG, and Merino-Sanjuan M. Intestinal Transport of Cefuroxime Axetil in Rats: Absorption and Hydrolysis Process. Int J Pharm 2002; 234:101–111PubMedCrossRefGoogle Scholar
  36. Sasinowska-Motyl M, Wisniewska I, Gumulka W, Oszczapowicz I, Szelachowska M, and Interewicz B. Esters of Cephalosporins. I. Permeability of Cefuroxime Liberated from its 1-Acetoxyethyl Ester through Biological Membranes; Influence of the Form and Size of the Ester Particles. Acta Pol Pharm1995; 52:391–395PubMedGoogle Scholar
  37. Tsuji A, Hirooka H, Tamai I, and Terasaki T. Evidence for a Carrier-Mediated Transport System in the Small Intestine Available for FK089, a New Cephalosporin Antibiotic Without an Amino Group. J Antibiot 1986, 39:1592–1597PubMedGoogle Scholar
  38. Webber JS and Wheeler WJ. Antimicrobial and Pharmacokinetic Properties of Newer Penicillins and Cephalosporins. In Morin GB, Gorman M. Chemistry and Biology of β-Lactam Antibiotics. London: Academic Press; 1982 (I):371–43.Google Scholar
  39. Welling PG, and Tse FLS. The Influence of Food on the Absorption of Antimicrobial Agents. J Antimicrob Chemother 1982; 9:7–27PubMedCrossRefGoogle Scholar
  40. Williams PEO and Harding SM. The Absolute Bioavailability of Oral Cefuroxime Axetil in Male and Female Volunteers After Fasting and After Food. J Antimicrob Chemother 1984, 13:191–196PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Tarra Fuchs
    • 1
  1. 1.Sunesis PharmaceuticalsSouth San FranciscoUSA

Personalised recommendations